Route 92 Medical has reached a settlement with Q’Apel Medical over an intellectual property dispute involving delivery catheter technology. The resolution includes the permanent removal of Q’Apel’s Hippo-Cheetah system from the market, which Route 92 claimed infringed on five of its U.S. patents.
Background and Resolution
- Route 92’s Tenzing delivery catheters, first used clinically in 2019, are protected by a global portfolio of over 140 patents, including 26 in the U.S.
- The October 2024 lawsuit, filed in the Delaware district court, accused Q’Apel’s Hippo aspiration and Cheetah delivery tools of violating patented Tenzing technology.
Dr. Tony Chou, CEO of Route 92, emphasized the company’s commitment to safeguarding its IP, noting that its Tenzing-powered systems continue to set a high standard in neurovascular stroke interventions.
Follow MEDWIRE.AI for updates on MedTech legal and innovation developments.
